2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Platelet Disorders, Thrombotic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4760 Targeting the extracellular ribonuclease–glycoRNA checkpoint restores megakaryocyte maturation and hemostatic recovery in immune thrombocytopenia

Jiaqian Qi, MD, PhD, Xiaofei Song2, Pufan Han3, Haohao Han4, Miao Jiang5, Depei Wu Sr, MD6, Han Yue, MD,PhD7
1 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
2 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
3 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
4 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
5 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
6 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China
7 National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, Jiangsu, China

Introduction: Immune thrombocytopenia (ITP) is driven not only by accelerated platelet clearance but also by ineffective thrombopoiesis, yet marrow-derived mechanisms that arrest megakaryocyte (MK) maturation remain poorly defined. Glycosylated RNAs (glycoRNAs) are sialylated N-glycan–modified RNAs displayed on cell surfaces and are intrinsically susceptible to extracellular ribonucleases (RNases). We investigated whether an RNase–glycoRNA axis contributes to defective platelet production in ITP.

 

Methods: We integrated bone marrow single-cell RNA sequencing from 5 patients with ITP and 4 healthy donors with biochemical analyses of an independent cohort (10/group). Healthy-donor CD34+ hematopoietic stem and progenitor cells (n=3 independent donors) were differentiated toward MKs in healthy or ITP marrow plasma with RNase A or RNase inhibitor (RI). Surface glycoRNA, viability, MK differentiation, polyploidization, PI−CD41+ platelet-like particle (PLP) production, and platelet-lineage secretory output were quantified. Mice with anti-CD42b-induced passive ITP received RNase A, RI, or vehicle (n=6/group), followed by serial platelet counts, marrow analyses, and tail bleeding.

 

Results: ITP MKs exhibited a proliferative-biased, less platelet-productive transcriptional state, with blunted N-glycosylation and sialylation programs along pseudotime. ITP marrow RNase activity was higher than control (2.05±0.07 vs 1.11±0.12 a.u./min; P=1.89×10−4), and spike-in RNA degradation increased from ΔCt 1.10±0.13 to 3.07±0.25 (P=8.0×10−6). RNASE3 protein increased 2.4-fold in ITP marrow (n=20/group), localized predominantly to activated eosinophil/neutrophil populations, correlated with RNase activity (r=0.68, P=0.001), and inversely correlated with platelet count and immature platelet fraction (r=-0.55, P=0.01).

ITP plasma reduced MK-surface glycoRNA, CD41 intensity, PLP production, polyploidization, and PF4, PDGF-BB, and TGF-β1 release. PLP output decreased from 18.3% to 8.3% and was restored to 17.0% by RI (P=0.004); median ≥8N MKs decreased from 70.3% to 49.5% and recovered to 66.8% with RI (P=0.008). RNase A phenocopied or intensified the ITP phenotype. Orthogonal ARPLA-based detection confirmed a 55% decrease in cell-surface glycoRNA; the signal was RNase- and neuraminidase-sensitive, persisted after denaturing proteinase K treatment, and was not explained by loss of viability (92.4% vs 90.8%; P=0.47). Recombinant human RNASE3 reproduced glycoRNA loss and reduced PLP output by 45%, whereas RNASE3 neutralization restored glycoRNA and PLPs by 65% (P=0.003); this rescue persisted after IgG depletion of ITP plasma.

In passive ITP, RI preserved marrow glycoRNA, accelerated platelet recovery, and reduced blood loss, rebleeding, and cumulative bleeding time, whereas RNase A produced reciprocal effects. RI reduced marrow RNase activity by 48%, increased normalized platelet-recovery area under the curve by 62%, shortened recovery to ≥50% baseline platelet counts from 12 to 8 days, changed day-15 reticulated platelets from 18.5% to 11.2%, and increased mature marrow MKs by 70% (all P<0.01). RNase-axis manipulation did not alter mature platelet aggregation to collagen, thrombin, or ADP.

 

Conclusions: These findings define an extracellular RNase–glycoRNA checkpoint that restrains terminal megakaryopoiesis in ITP. Human disease association, direct RNase perturbation, molecular rescue, and in vivo target engagement support the RNase–glycoRNA axis as a therapeutically targetable marrow pathway to relieve ineffective thrombopoiesis and improve hemostatic recovery.

Jiaqian Qi, MD, PhD: No relevant conflicts of interest to declare.